Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All-Reference-Cited by-同舟云学术

Live Attenuated Chimeric Yellow Fever Dengue Type 2 (ChimeriVax™-DEN2) Vaccine: Phase I Clinical Trial for Safety and Immunogenicity: Effect of Yellow Fever Pre-immunity in Induction of Cross Neutralizing Antibody Responses to All

Published:2006-03-03 Issue:2 Volume:2 Page:60-67
ISSN:1554-8600
Container-title:Human Vaccines
language:en
Short-container-title:Human Vaccines

Author:

Guirakhoo Farshad,Kitchener Scott,Morrison Dennis,Forrat Remi,McCarthy Karen,Nichols Richard,Yoksan Sutee,Duan Xiaochu,Ermak Thomas H.,Kanesa-Thasan Niranjan,Bedford Philip,Lang Jean,Quentin-Millet Marie-Jose,Monath Thomas P.

Publisher

Informa UK Limited

Subject

General Pharmacology, Toxicology and Pharmaceutics,Immunology

Link

http://www.tandfonline.com/doi/pdf/10.4161/hv.2.2.2555

Cited by 175 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Development of a hydrogen peroxide-inactivated vaccine that protects against viscerotropic yellow fever in a non-human primate model;Cell Reports Medicine;2024-07

2. Self-Replicating RNA Derived from the Genomes of Positive-Strand RNA Viruses;Methods in Molecular Biology;2024

3. Rise of the RNA machines – self-amplification in mRNA vaccine design;Trends in Biotechnology;2023-11

4. The G285S mutation in nsP1 is sufficient to render Sindbis virus as a stable vector for gene delivery;Frontiers in Microbiology;2023-07-20

5. Immunogenicity and safety of concomitant and sequential administration of yellow fever YF-17D vaccine and tetravalent dengue vaccine candidate TAK-003: A phase 3 randomized, controlled study;PLOS Neglected Tropical Diseases;2023-03-08